Dr. Agnes Chen, MD
Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)
1000 W Carson St, Box 468
Torrance, CA 90502
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2007
Licensed in California since 2002, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology with Special Qualifications in Child Neurology Physician primary
CA license A80127 (first issued 2002; current) -
Neurology Physician
CA license A80127 (first issued 2002; current) -
Pediatrics Physician
CA license A80127 (first issued 2002; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carbamazepine Er (carbamazepine) Other prescribers in Torrance, CA | 12 |
| Hydrocortisone Other prescribers in Torrance, CA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $71.34 in total to this clinician.
| Cleerly, Inc. | $55.97 |
|---|---|
| Amgen Inc. | $15.37 |
| Food and Beverage | $71.34 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $139,396 in research payments for these studies, mostly to the institutions running them.
- A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT03771898 - Post-Trial Access (PTA) Program for Patients with Metachromatic Leukodystrophy who Received the Drug SHP611 While Participating in the SHP611-201 or HGT-MLD-070/071 studies
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.